Topical tamoxifen - A potential therapeutic regime in treating excessive dermal scarring?

British Journal of Plastic Surgery

Volumn 51, Issue 6, 1998, Pages 462-469

  Hu, D ^a   Hughes, M A ^a   Cherry, G W ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; TAMOXIFEN; TETRAZOLIUM;

ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SCAR FORMATION;

EID: 0032167774     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjps.1997.0100     Document Type: Article

References (40)

1. 1. Mancoll JS, McCauley RL, Phillips LG. The inhibitory effect of tamoxifen on keloid fibroblasts. Surgical Forum 1996; 47: 718-20.
2. 2. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983; 52: 2201-4.
3. 3. Procter H, Singh L, Baum M, Brinkley D. Response of multicentric desmoid tumours to tamoxifen. Br J Surg 1987; 74: 401.
4. 4. Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumours treated with triphenylethylenes. Eur J Cancer 1992; 28: 1014-8.
5. 5. Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991; 109: 502-6.
6. 6. Owens LV, Cance WG, Huth JF. Retroperitoneal fibrosis treated with tamoxifen. Am Surg 1995; 61: 842-4.
7. 7. Adams LW, Priestley GC. Contraction of collagen lattices by skin fibroblasts: drug-induced changes. Arch Dermatol Res 1988; 280: 114-8.
8. 8. Dubertret L, Coulomb B. Dermo-Epidermal Interactions, Wound Healing and Psoriasis. In T.J. Ryan (Ed.), Beyond Occlusion: Dermatology Proceedings (Int. Congress Symp. Series, No. 137.R). London: Society of Medicine, 1988; 19.
9. 9. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-10.
10. 10. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 1979; 76: 1274-8.
11. 11. Montesano R, Orci L. Transforming growth factor-β stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA 1988; 85: 4894-7.
12. 12. Hughes MA, Cherry G, Dawber RPR, Ryan TJ. Minoxidil-induced changes in the contraction of collagen lattices by human skin fibroblasts. Plast Reconstr Surg 1992; 89: 722-30.
13. 13. Delvoye P, Nusgens B, Lapière CM. The capacity of retracting a collagen matrix is lost by dermatosparatic skin fibroblasts. J Invest Dermatol 1983; 81: 267-70.
14. 14. Linares HA, Larson DL. Proteoglycans and collagenase in hypertrophic scar formation. Plast Reconstr Surg 1978; 62: 589-93.
15. 15. MacNeil S, Wagner M, Kirkham PR, et al. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 1993; 3: 67-74.
16. 16. Greco RM, Erhlich HP. Differences in cell division and thymidine incorporation with rat and primate fibroblasts in collagen lattices. Tissue and Cell 1992; 24: 843-51.
17. 17. Parish JL, Hughes MA, Cherry GW, Ferguson DJP. The effect of minoxidil analogues and metabolites on the contraction of collagen lattices by human skin fibroblasts. Br J Plastic Surg 1995; 48: 154-60.
18. 18. Jordan VC. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. J Natl Cancer Inst 1992; 84: 231-4.
19. 19. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991; 51: 4837-44.
20. 20. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69: 2961-4.
21. 21. Pujol H, Girault J, Rouanet P, Fournier S, Freuer J, Simony J, et al. Phase 1 study of percutaneous 4-hydroxytamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol 1995; 36: 493-8.
22. AA as catalyst of 4-hydroxylation induced by TCDD and bNF. Cancer Res 1994; 54: 3140-4.
23. 23. Maenpaa J, Dooley T, Wurz G, et al. Topical toremifene: a new approach for cutaneous melanoma? Cancer Chemother Pharmacol 1993; 32: 392-5.
24. 24. Lee RC, Doong H, Jellema AF. The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 1994; 129: 107-11.
25. 25. Gagliardi AR, Henig B, Collins DC. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996; 16: 1101-6.
26. 26. Parrelli JM, Meisler N, Cutroneo KR. Abrogation of the fibrotic effect of transforming growth factor b in dermal wound healing. Wound Rep Reg 1997; 5: 136-40.
27. 27. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405-9.
28. 28. Mancoll JS, Chau D, Munger J, et al. Tamoxifen downregulates TGF-β production by keloid fibroblasts. Surgical Forum 1997; 48: 704-7.
29. 29. Clark RAF, McCoy GA, Folkvord JM, McPherson JM. TGF-β1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event. J Cell Physiol 1997; 170: 69-80.
30. 30. Schmid P, Itin P, Cherry G, Bi C, Cox DA. Enhanced Expression of Transforming Growth factor-β Type I and Type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 1998; 152: 485-93.
31. 31. Sato M, Iishikawa O, Abe M, Miyachi Y. Opposite effects of tumour necrosis factor-a on type I and III collagen gene expression by human dermal fibroblasts in monolayer and three-dimensional cultures. Br J Dermatol 1998; 138: 118-21.
32. 32. MacNeil S, Wagner M, Rennie IG. Investigation of the role of signal transduction in attachment of ocular melanoma cells to matrix proteins: inhibition of attachment by calmodulin antagonists including tamoxifen. Clin Exp Metastasis 1994; 12: 375-84.
33. 33. Ehrlich HP, Rajaratnam JBM. Cell locomotion forces versus cell contraction forces for collagen lattice contraction: an in vitro model of wound contraction. Tissue Cell 1990; 22: 407-17.
34. 34. Ehrlich HP, Buttle DJ, Bernanke DH. Physiological variables affecting collagen lattice contraction by human dermal fibroblasts. Exp Mol Pathol 1989; 50: 220-9.
35. 35. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146: 56-66.
36. 36. Appleton I, Brown NJ, Willoughby DA. Apoptosis, Necrosis and Proliferation: Possible implication in the etiology of keloids. Am J Pathol 1996; 149: 1441-7.
37. 37. Garner WL, Rittenberg T, Ehrlich HP, et al. Hypertrophic scar fibroblasts accelerate collagen gel contraction. Wound Rep Reg 1995; 3: 185-91.
38. Dahai Hu MD, formerly Registrar, Burns Unit, Xijing Hospital,The Fourth Military Medical University, Xi'an, Shaanxi, PR China. Now Research Fellow, Wound Healing Institute, Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK.
39. Margaret A. Hughes PhD, Director, Cell Culture and Wound Healing Laboratories, Wound Healing Institute, Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK.
40. George W. Cherry DPhil, Chairman, Wound Healing Institute, Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK. Correspondence to Dr Margaret A. Hughes.